Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen

Mansoura University Department of Histopathology Mansoura Egypt
Breast Cancer Research and Treatment (Impact Factor: 3.94). 02/2009; 119(2):283-293. DOI: 10.1007/s10549-009-0345-x
Source: PubMed


Transferrin receptor (CD71) is involved in the cellular uptake of iron and is expressed on cells with high proliferation.
It may be implicated in promoting the growth of endocrine resistant phenotypes within ER+/luminal-like breast cancer. We used
a panel of in vitro cell models of acquired resistance to tamoxifen (TAMR), Faslodex (FASR) or severe oestrogen deprivation
(MCF-7X) and the ER+ luminal MCF-7 parental line to determine CD71 mRNA expression and to study transferrin (Tf) effects on
in vitro tumour growth and its inhibition. Furthermore, CD71 protein expression was assessed in a well-characterized series
of patients with invasive breast carcinoma using tissue microarrays. Our results demonstrated a striking elevation of CD71
in all cell models of acquired resistance. Exogenous Tf significantly promoted growth in MCF-7-X and MCF-7 cells but more
so in MCF-7-X; this growth was significantly reduced by Faslodex (FAS) or a phosphoinositide-3 kinase inhibitor (LY294002).
Increased CD71 expression was associated with poor NPI score, tumour proliferation, basal CKs, p53, EGFR, HER2, steroid receptor
negativity and shortened breast cancer specific survival (P<0.001). On multivariate analysis, CD71 was found to be an independent prognostic factor in the ER+ cohort of patients.
In conclusion, therapies of current interest in breast cancer (e.g. FAS, PI3K-inhibitors) appear able to partially impact
on transferrin/CD71-promoted growth, but further investigation of this important mitogenic mechanism may assist in designing
new therapeutic strategies to target highly proliferative, endocrine resistant breast cancers. CD71 appears to be a candidate
marker of a subgroup of ER+/luminal-like breast cancer characterised by poor outcome and resistance to tamoxifen.

Download full-text


Available from: Mohammed A Aleskandarany
    • "Animal models point to the importance of iron-loaded Tf in malignancy, with the notion that the TfR is up-regulated on cancer cells in order to satisfy the increased iron demand. Along these lines, TfR serves as a marker of poor prognosis and predicts the sensitivity of breast cancer treatment to tamoxifen (Habashy et al. 2010). Tumor cells also express high levels of ferritin to meet their increasing iron demand and down-regulation of ferritin increased the sensitivity of cells to chemotherapeutics (Shpyleva et al. 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Macrophages are central in regulating iron homeostasis, which is tightly linked to their versatile role during innate immunity. They sequester iron by phagocytosis of senescent erythrocytes and represent a major source of available iron in the body. Macrophage iron homeostasis is coupled to the functional heterogeneity and plasticity of these cells, with their extreme roles during inflammation, immune modulation, and resolution of inflammation. It is now appreciated that the macrophage polarization process dictates expression profiles of genes involved in iron metabolism. Therefore, macrophages have evolved a multitude of mechanisms to sequester, transport, store, and release iron. A new, enigmatic protein entering the iron scene and affecting the macrophage phenotype is lipocalin-2. Iron sequestration in macrophages depletes the microenvironment, thereby limiting extracellular pathogen or tumor growth, while fostering inflammation. In contrast, iron release from macrophages contributes to bystander cell proliferation, which is important for tissue regeneration and repair. This dichotomy is also reflected by the dual role of lipocalin-2 in macrophages. Unfortunately, the iron release macrophage phenotype is also a characteristic of tumor associated macrophages and stimulates tumor cell survival and growth. Iron sequestration versus its release is now appreciated to be associated with the macrophage polarization program and can be used to explain a number of biological functions attributed to distinct macrophage phenotypes. Here we discuss macrophage iron homeostasis with a special focus on lipocalin-2 related to the formation and function of tumor associated macrophages.
    No preview · Article · Sep 2014 · Immunobiology
  • Source
    • "This androgen-dependent interaction between PTCs and Sertoli cells has been suggested to be mediated by PModS, a molecule secreted by PTCs that modulates the secretion of transferrin, inhibin and androgen-binding protein by Sertoli cells (Verhoeven et al., 2000), although other PTC-derived factors, such as IGF-I, bFGF and several cytokines, share most of the PModS effects on Sertoli cells, and thus could also participate in its functional regulation (Verhoeven et al., 2000). Interestingly enough, alterations in transferrin and inhibin levels have been related with an increased invasiveness and poor prognosis in several tumour types (Mylonas et al., 2005; Balanathan et al., 2009; Park et al., 2009; Habashy et al., 2010). Moreover, the analysis of the rodent model has shown that PTCs are also involved in the regulation of processes such as spermatogenesis and testicular development (Mackay & Smith, 2007) through the secretion of factors that includes Fibroblast Growth Factors (El Ramy et al., 2005), TGF-b (Konrad et al., 2000a) and ECM components (Ailenberg et al., 1988). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The tumour surrounding stroma, known as reactive stroma, is a crucial factor to understand cancer cell growth and invasion. In the normal adult testis, the stroma contains extracellular matrix components, fibroblasts, infiltrating leucocytes, lymphocytes, macrophages and capillaries, as well as other specific cell populations, like Leydig cells and a thin myoepithelium surrounding the seminiferous tubules constituted by the peritubular cells. All these cells are an important source of proliferation and survival promoting signals, proteolytic enzymes, migratory cues and pro-angiogenic factors. Ascribable to this pro-invasive activity, the tumour reactive stroma cells, especially cancer-associated myofibroblasts, have emerged as a promising target for cancer therapy. This review is focused on the potential role of the peritubular myoid cells in the development of testicular germ cell tumours as the precursors of cancer-associated myofibroblast and on an experimental model for the study of testis germinal cancer stroma and on the differences between normal and tumour-associated stromal cells, including the molecular mechanisms that mediate the important cancer stroma crosstalk. Special attention will be paid to the cancer-associated myofibroblasts as possible therapeutic targets, because they are one of the main components of the reactive stroma and are known to secrete a variety of paracrine factors that stimulate tumour progression.
    Full-text · Article · May 2011 · International Journal of Andrology
  • Source
    • "These two receptors are of interest as both are known to be up-regulated in cancers. In particular, EGFR has been shown to be up-regulated in various cancers involving the head and neck (Gold et al., 2009), lung (Dy and Adjei, 2009), gliomas (Kesari et al., 2006) and ovaries (Lafky et al., 2008); while TfR is known to be overexpressed in breast cancer (Habashy et al., 2010). As such, EGFR and TfR have become prime targets in the development of cancer therapies (Lepelletier et al., 2007; Capdevila et al., 2009), and hence, they are also the focus of our current study. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Andrographolide is the active component of Andrographis paniculata, a plant used in both Indian and Chinese traditional medicine, and it has been demonstrated to induce apoptosis in different cancer cell lines. However, not much is known about how it may affect the key receptors implicated in cancer. Knowledge of how andrographolide affects receptor trafficking will allow us to better understand new mechanisms by which andrographolide may cause death in cancer cells. We utilized the well-characterized epidermal growth factor receptor (EGFR) and transferrin receptor (TfR) expressed in epidermoid carcinoma (A-431) cells as a model to study the effect of andrographolide on receptor trafficking. Receptor distribution, the total number of receptors and surface receptors were analysed by immunofluorescence, Western blot as well as flow-cytometry respectively. Andrographolide treatment inhibited cell growth, down-regulated EGFRs on the cell surface and affected the degradation of EGFRs and TfRs. The EGFR was internalized into the cell at an increased rate, and accumulated in a compartment that co-localizes with the lysosomal-associated membrane protein in the late endosomes. This study sheds light on how andrographolide may affect receptor trafficking by inhibiting receptor movement from the late endosomes to lysosomes. The down-regulation of EGFR from the cell surface also indicates a new mechanism by which andrographolide may induce cancer cell death.
    Preview · Article · Mar 2010 · British Journal of Pharmacology
Show more